Editing Mesothelioma Treatment Centers (section)

== What Clinical Trials Offer New Hope for Mesothelioma Patients? ==

The clinical trial landscape for mesothelioma has expanded dramatically with '''over 70 actively recruiting studies''' representing unprecedented therapeutic innovation. Patients participating in clinical trials gain access to cutting-edge treatments unavailable through standard care while contributing to research that will benefit future patients.<ref>[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical Trials for Mesothelioma Treatment], Mesothelioma.net</ref>

=== Pivotal Ongoing Trials ===

'''DREAM3R Trial (NCT04334759)''': This Phase III study comparing durvalumab with chemotherapy against physician's choice treatment has enrolled 534 patients across 57 global sites. Results may establish a new first-line standard of care. Patients interested in enrollment can inquire through their mesothelioma treatment center or discuss eligibility requirements with their oncologist.

'''eVOLVE-Meso Trial (NCT06097728)''': Launched in November 2023, this study tests volrustomig, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy in '''825 patients'''—representing one of the largest mesothelioma trials ever conducted. Primary completion is expected in March 2027, with results potentially reshaping treatment paradigms.

'''CAR-T Cell Programs''': Memorial Sloan Kettering's mesothelin-targeted CAR-T programs achieve '''23.9 months median overall survival''' when combined with pembrolizumab. The STAR-101 study testing SynKIR-110 CAR-T cells received FDA Fast Track designation in 2023, while the National Cancer Institute's TNhYP218 trial recently launched recruitment for 100 patients with advanced CAR design promising improved durability.

=== Immunotherapy Breakthroughs ===

{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ️ Research Milestone:''' The CheckMate 743 follow-up demonstrates that nivolumab plus ipilimumab achieves '''28% durable response at three years'''—compared to 0% for chemotherapy alone—fundamentally transforming treatment goals from palliation to potential long-term disease control.
|}

The FDA's September 2024 approval of pembrolizumab with chemotherapy, based on KEYNOTE-483 results showing '''17.3 months median overall survival''', provides another first-line option demonstrating nearly three-fold improvement in response rates. This approval expands treatment options available at community oncology practices, not just specialized centers.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>

According to Rod De Llano of Danziger & De Llano, "Clinical trial participation represents both a treatment opportunity and documentation opportunity for our clients. The detailed medical records generated during trial participation often strengthen compensation claims by establishing clear causation links between asbestos exposure and disease development."<ref>[https://dandell.com/lawyers/rod-de-llano/ Rod De Llano Attorney Profile], Danziger & De Llano</ref>

----